Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations'), We wish to inform you that Board of Directors of the Company at its meeting held today i.e., July 23, 2021, based on the recommendation of the Nomination and Remuneration Committee, appointed Dr. Vajja Sambasiva Rao (DIN: 09233939), as additional and an Independent Director effective from July 23, 2021 for a period of 5 (five) years, subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company. The Board also approved investment of Rs 2.50 lakh (equivalent to 25% stake) by way of subscription in the new associate company - Rising Pharma Specialities Pvt. Ltd., under incorporation in India to take care of back office operations relating to Regulatory, Accounting, Information and Technology and other Logistic Services for Rising Pharma Holdings, Inc., USA.
23-07-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Statement Of Investor Complaints For The Quarter Ended June 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 118190 Name of the Signatory :- K HANUMANTHA RAODesignation :- Company Secretary and Compliance Officer
20-07-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Shareholding for the Period Ended June 30, 2021

 Suven Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here
19-07-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, please find enclosed herewith the Confirmation Certificates issued by KFin Technologies Private Limited, Registrar and Share Transfer Agents of the Company, for the quarter ended June 30, 2021.
12-07-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

 Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the year ended 31st March, 2021.
07-07-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window

 We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 01st July, 2021 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter ending on 30th June, 2021, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is for your information and record.
30-06-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 With reference to above subject, please find enclosed herewith the Annual Secretarial Compliance Report for the financial year ended 31st March, 2021, issued by Practicing Company Secretary, under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019.
17-06-2021

Suven Pharma Consolidated March 2021 Net Sales at Rs 259.16 crore, up 40.27% Y-o-Y

 NULL
11-06-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the above subject, please find enclosed News Release of our company titled 'CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG.' In this connection, please further note that the TRADING WINDOW for dealing in the securities of the company which was closed from 01st April, 2021 as per PIT Code of the Company stands extended till 13th June, 2021. The trading window will be opened from 14th June, 2021. This is for your information and record.
10-06-2021

CSIR-IICT, Suven Pharma ink MoU for covid drugs Molnupiravir, 2-DG

 The antiviral drug initially developed to treat influenza is repurposed to suppress the Covid virus transmission within 24 hours, completely.
10-06-2021
Next Page
Close

Let's Open Free Demat Account